胃癌生物治療現狀與展望_《中國普外基礎與臨床雜志》

作者：

朱金明 , 余佩武

第三軍醫大學西南醫院普外Ⅰ科（重慶400038）;

關鍵詞：

胃癌生物治療

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的探討胃癌生物治療的現狀與研究進展。
方法采用文獻回顧的方法對胃癌生物治療現狀及其研究進展進行綜述。
結果胃癌生物治療的研究內容及主要方法包括：免疫調節劑治療，單克隆抗體及其交聯物導向治療，細胞因子治療，過繼免疫治療，基因治療等。
結論生物治療作為手術和放/化療的有益補充，在胃癌綜合治療中發揮著重要的輔助作用。

引用本文： 朱金明,余佩武. 胃癌生物治療現狀與展望. 中國普外基礎與臨床雜志, 2004, 11(2): 127-129. doi: 復制

1.	Jung YD, Mansfield PF, Akagi M, et al. Effects of combination antivascular endothelial growth factor receptor and antiepidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model [J]. Eur J Cancer, 2002; 38(8)∶1133.
2.	Matsumoto K, Konno H, Tanaka T, et al. Combination therapy with vascular endothelial growth factor neutralizing antibody and mitomycin C on human gastric cancer xenograft [J]. Jpn JCancer Res, 2000; 91(7)∶748.
3.	Sasaki S, Ozeki I, Takekawa M, et al. Antibody treatment for cancer [J]. Nippon Geka Gakkai Zasshi, 2000; 101(9)∶607.
4.	Parmiani G, Rivoltini L, Andreola G, et al. Cytokines in cancer therapy [J]. Immunol Lett, 2000; 74(1)∶41.
5.	Penichet ML, Morrison SL. Antibodycytokine fusion proteins for the therapy of cancer [J]. J Immunol Methods, 2001; 248(1-2)∶91.
6.	Yamaue H, Tanimura H, Mizobata S, et al. Multidisciplinary treatment for gastric cancer patients by chemoimmunotherapy [J]. Hepatogastroenterology, 1999; 46(25)∶620.
7.	Yamaguchi Y, Ohta K, Shimizu K, et al. Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin2 [J].Anticancer Res, 2001; 21(1B)∶669.
8.	Tsunoda T, Tanimura H, Yamaue H, et al. Tumor specific CTL therapy for advanced cancer and development for cancer vaccine [J]. Hepatogastroenterology, 1999; 46（Suppl 1）∶1287.
9.	Banchereau J, Steinman RM. Dendritic cells and the control of immunity [J]. Nature, 1998; 392(6673)∶245.
10.	Nair SK, Morse M, Boczkowski D, et al. Induction of tumorspecific cytotoxic T lymphocytes in cancer patients by autologous tumor RNAtransfected dendritic cells [J].Ann Surg, 2002; 235(4)∶540.
11.	孫黎飛, 劉江, 曹雪濤, 等. IL2基因修飾增強樹突狀細胞抗原提呈功能及其機制 [J]. 中華血液學雜志, 2002; 23(5)∶247.
12.	章衛平, 何龍, 曹雪濤. 淋巴細胞趨化因子基因修飾增強腫瘤抗原多肽致敏的樹突狀細胞的抗腫瘤免疫效果 [J]. 中華醫學雜志, 1999; 79(3)∶170.
13.	Gong J, Avigan D, Chen D, et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells [J]. Proc Natl Acad Sci USA, 2000; 97(6)∶2715.
14.	Pulendran B, Lingappa J, Kennedy MK, et al. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice [J]. J Immunol, 1997; 159(5)∶2222.
15.	Yi Q, Desikan R, Barlogie B, et al. Optimizing dendritic cellbased immunotherapy in multiple myeloma [J]. Br J Haematol, 2002; 117(2)∶297.
16.	余文林, 黃宗海. 自殺基因治療胃腸道腫瘤的研究進展 [J]. 中國普外基礎與臨床雜志, 1999; 6(3)∶781.
17.	Naka K, Yokozaki H, Yasui W, et al. Effect of antisense human telomerase RNA transfection on the growth of human gastric cancer cell lines [J]. Biochem Biophys Res Commun, 1999; 255(3)∶753.
18.	Steele RJ, Lane DP. Gene therapy for gastric cancer: problems and prospects [J]. Surg Oncol, 2000; 9(1)∶13.
19.	Vile RG, Russell SJ, Lemoine NR. Cancer gene therapy: hard lessons and new courses [J]. Gene Ther, 2000; 7(1)∶2.
20.	錢其軍, 車小燕, 岑信棠, 等. 基因病毒載體的研制及其抗腫瘤作用的初步研究 [J]. 中華醫學雜志, 2002; 82(8)∶557.
21.	Smith ER, Chiocca EA. Oncolytic viruses as novel anticancer agents: turning one scourge against another [J]. Expert Opin Investig Drugs, 2000; 9(2)∶311.
22.	Hermiston T. Gene delivery from replicationselective viruses: arming guided missiles in the war against cancer [J]. J Clin Invest, 2000; 105(9)∶1169.
23.	Kim R, Minami K, Nishimoto N, et al. Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer [J]. Int J Oncol, 2001; 18(2)∶363.
24.	劉君, 李寧, 宋少柏. 胃癌的分子生物學研究進展 [J]. 中國普外基礎與臨床雜志, 2000; 7(3)∶791.
25.	Mologni L, Marchesi E, Nielsen PE, et al. Inhibition of promyelocytic leukemia (PML)/retinoic acid receptoralpha and PML expression in acute promyelocytic leukemia cells by antiPML peptide nucleic acid [J]. Cancer Res, 2001; 61(14)∶5468.

1. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination antivascular endothelial growth factor receptor and antiepidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model [J]. Eur J Cancer, 2002; 38(8)∶1133.
2. Matsumoto K, Konno H, Tanaka T, et al. Combination therapy with vascular endothelial growth factor neutralizing antibody and mitomycin C on human gastric cancer xenograft [J]. Jpn JCancer Res, 2000; 91(7)∶748.
3. Sasaki S, Ozeki I, Takekawa M, et al. Antibody treatment for cancer [J]. Nippon Geka Gakkai Zasshi, 2000; 101(9)∶607.
4. Parmiani G, Rivoltini L, Andreola G, et al. Cytokines in cancer therapy [J]. Immunol Lett, 2000; 74(1)∶41.
5. Penichet ML, Morrison SL. Antibodycytokine fusion proteins for the therapy of cancer [J]. J Immunol Methods, 2001; 248(1-2)∶91.
6. Yamaue H, Tanimura H, Mizobata S, et al. Multidisciplinary treatment for gastric cancer patients by chemoimmunotherapy [J]. Hepatogastroenterology, 1999; 46(25)∶620.
7. Yamaguchi Y, Ohta K, Shimizu K, et al. Generation of cytotoxic effector lymphocytes by MLTC using tumor cells genetically modified to secrete interleukin2 [J].Anticancer Res, 2001; 21(1B)∶669.
8. Tsunoda T, Tanimura H, Yamaue H, et al. Tumor specific CTL therapy for advanced cancer and development for cancer vaccine [J]. Hepatogastroenterology, 1999; 46（Suppl 1）∶1287.
9. Banchereau J, Steinman RM. Dendritic cells and the control of immunity [J]. Nature, 1998; 392(6673)∶245.
10. Nair SK, Morse M, Boczkowski D, et al. Induction of tumorspecific cytotoxic T lymphocytes in cancer patients by autologous tumor RNAtransfected dendritic cells [J].Ann Surg, 2002; 235(4)∶540.
11. 孫黎飛, 劉江, 曹雪濤, 等. IL2基因修飾增強樹突狀細胞抗原提呈功能及其機制 [J]. 中華血液學雜志, 2002; 23(5)∶247.
12. 章衛平, 何龍, 曹雪濤. 淋巴細胞趨化因子基因修飾增強腫瘤抗原多肽致敏的樹突狀細胞的抗腫瘤免疫效果 [J]. 中華醫學雜志, 1999; 79(3)∶170.
13. Gong J, Avigan D, Chen D, et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells [J]. Proc Natl Acad Sci USA, 2000; 97(6)∶2715.
14. Pulendran B, Lingappa J, Kennedy MK, et al. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice [J]. J Immunol, 1997; 159(5)∶2222.
15. Yi Q, Desikan R, Barlogie B, et al. Optimizing dendritic cellbased immunotherapy in multiple myeloma [J]. Br J Haematol, 2002; 117(2)∶297.
16. 余文林, 黃宗海. 自殺基因治療胃腸道腫瘤的研究進展 [J]. 中國普外基礎與臨床雜志, 1999; 6(3)∶781.
17. Naka K, Yokozaki H, Yasui W, et al. Effect of antisense human telomerase RNA transfection on the growth of human gastric cancer cell lines [J]. Biochem Biophys Res Commun, 1999; 255(3)∶753.
18. Steele RJ, Lane DP. Gene therapy for gastric cancer: problems and prospects [J]. Surg Oncol, 2000; 9(1)∶13.
19. Vile RG, Russell SJ, Lemoine NR. Cancer gene therapy: hard lessons and new courses [J]. Gene Ther, 2000; 7(1)∶2.
20. 錢其軍, 車小燕, 岑信棠, 等. 基因病毒載體的研制及其抗腫瘤作用的初步研究 [J]. 中華醫學雜志, 2002; 82(8)∶557.
21. Smith ER, Chiocca EA. Oncolytic viruses as novel anticancer agents: turning one scourge against another [J]. Expert Opin Investig Drugs, 2000; 9(2)∶311.
22. Hermiston T. Gene delivery from replicationselective viruses: arming guided missiles in the war against cancer [J]. J Clin Invest, 2000; 105(9)∶1169.
23. Kim R, Minami K, Nishimoto N, et al. Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer [J]. Int J Oncol, 2001; 18(2)∶363.
24. 劉君, 李寧, 宋少柏. 胃癌的分子生物學研究進展 [J]. 中國普外基礎與臨床雜志, 2000; 7(3)∶791.
25. Mologni L, Marchesi E, Nielsen PE, et al. Inhibition of promyelocytic leukemia (PML)/retinoic acid receptoralpha and PML expression in acute promyelocytic leukemia cells by antiPML peptide nucleic acid [J]. Cancer Res, 2001; 61(14)∶5468.

《中國普外基礎與臨床雜志》

胃癌生物治療現狀與展望

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

胃癌生物治療現狀與展望

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料